

SJG-136

Catalog No: tcsc4593



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg



Specifications

CAS No:

232931-57-6

Formula:

$C_{31}H_{32}N_4O_6$

Pathway:

Cell Cycle/DNA Damage

Target:

DNA Alkylator/Crosslinker

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

NSC-694501

Observed Molecular Weight:

556.61


Product Description

SJG-136 is a **DNA cross-linking** agent, with an **XL₅₀** of 45 nM for pBR322 DNA; SJG-136 has potent antitumor activity.

IC50 & Target: XL50: 45 nM (pBR322 DNA)^[1]

In Vitro: SJG-136 (dimer 5) is a DNA cross-linking agent, with an XL₅₀ (concentration of agent required for 50% cross-linking of pBR322 DNA) of 45 nM for pBR322 DNA. SJG-136 is cytotoxic to ovarian cell lines, such as A2780 (IC₅₀, 22.5 pM), A2780cisR (IC₅₀, 24 pM), CH1 (IC₅₀, 0.12 nM), CH1cisR (IC₅₀, 0.6 nM), and SKOV-3 (IC₅₀, 9.1 nM)^[1]. SJG-136 (SG2000) also reduces the viability of a panel of canine cancer cells, with GI₅₀ values ranging from 0.33 - >100 nM after a 1 h exposure, and [2].

In Vivo: SJG-136 shows more potent antitumor effect against CMeC-1 tumour at 0.30 mg/kg than 0.15 mg/kg either as a single dose or administered once a week for three weeks via dosed intravenously in mice. SJG-136-induced H2AX phosphorylation shows good correspondence, but less sensitivity, than measurement of foci^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!